Buscar en
Revista Colombiana de Reumatología
Toda la web
Inicio Revista Colombiana de Reumatología Vasculopatía livedoide debida a síndrome antifosfolípido
Información de la revista
Vol. 18. Núm. 4.
Páginas 311-316 (Diciembre 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 18. Núm. 4.
Páginas 311-316 (Diciembre 2011)
DOI: 10.1016/S0121-8123(11)70047-0
Acceso a texto completo
Vasculopatía livedoide debida a síndrome antifosfolípido
Livedoid vasculopathy due to antiphospholipid syndrome
Visitas
...
Juan Pablo Restrepo1,
Autor para correspondencia
jprestrepo@lycos.com

Correspondencia.
, María del Pilar Molina2
1 Internista-Reumatólogo. Profesor de la Universidad del Quindío
2 Médica y cirujana. Universidad Libre
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

La vasculopatía livedoide es una entidad rara y crónica que afecta predominantemente los miembros inferiores. La etiología de la enfermedad es desconocida, pero en la histopatología se observa trombosis en la dermis sin compromiso inflamatorio de la pared del vaso. Se manifiesta por lesiones petequiales y por ulceraciones que sanan con cicatrices hiperpigmentadas alternando con áreas blanquecinas. Se han empleado múltiples tratamientos hasta el momento, sin total éxito.

Palabras clave:
síndrome antifosfolípido
livedo reticularis
fisiopatología
terapia
Summary

Livedoid vasculopathy is a rare, chronic disease that affects predominantly the lower limbs. The etiology of the disease is unknown, but histopathology shows thrombosis in the dermis without inflammatory changes in the vessel wall. It is manifested by petechial lesions and ulcerations that heal with scarring hyperpigmentation alternating with white areas. Multiple treatments have been used so far, without total success.

Key words:
antiphospholipid syndrome
reticularis livedo
pathophysiology
therapy
El Texto completo está disponible en PDF
Referencias
[1.]
B. Hairston, M. Davis, M. Pittelkow, I. Ahmed.
Livedoid vasculopathy: further evidence for procoagulant pathogenesis.
Arch Dermatol, 142 (2006), pp. 1413-1418
[2.]
J. Bard, R. Winkelmann.
Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis.
Arch Dermatol, 96 (1967), pp. 489-499
[3.]
G. Milian.
Les atrophies cutanées syphilitiques.
Bull Soc Franc Derm Syph, 36 (1929), pp. 865-871
[4.]
R. Winkelmann, A. Schroeter, R. Kierland, T. Ryan.
Clinical studies of livedoid vasculitis: segmental hyalinizing vasculitis.
Mayo Clin Proc, 49 (1974), pp. 746-750
[5.]
M. Papi, B. Didona, O. De Pita, L. Silvestri, G. Ferranti, M. Gantcheva, L. Chinni.
PURPLE (atrophie blanche): Clinical, histological and immunological study of twelve patients.
J Eur Acad Dermatol Venereol, 9 (1997), pp. 129-133
[6.]
M. Maessen-Visch, M. Koedam, K. Hamulyák, H. Neumann.
Atrophie blanche.
Int J Dermatol, 38 (1999), pp. 161-172
[7.]
K. Tsutsui, F. Shirasaki, M. Takata, K. Takehara.
Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation.
Dermatol, 192 (1996), pp. 120-124
[8.]
M. Baccard, M. Vignon-Pennamen, M. Janier, M. Scrobohaci, L. Dubertret.
Livedo vasculitis with protein C system deficiency.
Arch Dermatol, 128 (1992), pp. 1410-1411
[9.]
B. Hegemann, P. Helmbold, W. Marsch.
Livedoid vasculitis with ulcerations: the role of antithrombin III deficiency and its therapeutic consequences.
Arch Dermatol, 138 (2002), pp. 841-842
[10.]
C. Drucker, W. Duncan.
Antiplatelet therapy in atrophie blanche and livedo vasculitis.
J Am Acad Dermatol, 7 (1982), pp. 359-363
[11.]
F. Meiss, W. Marsch, M. Fischer.
Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences.
Eur J Dermatol, 16 (2006), pp. 159-162
[12.]
I. Uthman, M. Khamashta.
Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome.
J Rheumatol, 33 (2006), pp. 2379-2382
[13.]
C. Grattan, J. Burton, A. Boon.
Sneddon's syndrome (livedo reticularis and cerebral thrombosis) with livedo vasculitis and anticardiolipin antibodies.
Br J Dermatol, 120 (1989), pp. 441-447
[14.]
K. Acland, A. Darvay, S. Wakelin, R. Russell-Jones.
Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?.
Br J Dermatol, 140 (1999), pp. 131-135
[15.]
J. Grob, J. Bonerandi.
Thrombotic skin disease as a marker of the anticardiolipin syndrome. Livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity.
J Am Acad Dermatol, 20 (1989), pp. 1063-1069
[16.]
A. Leonard, M. Pomeranz, A. Franks Jr..
A case of livedoid vasculopathy in a 22-year-old man.
J Drugs Dermatol, 3 (2004), pp. 678-679
[17.]
S. In, J. Han, H. Kang, E. Lee, Y. Kim.
The histopathological characteristics of livedo reticularis.
J Cutan Pathol, 36 (2009), pp. 1275-1278
[18.]
A. Shimizu, A. Tamura, M. Yamanaka, H. Amano, Y. Nagai, O. Ishikawa.
Case of livedoid vasculopathy with extensive dermal capillary thrombi.
[19.]
L. Gibson, W. Su.
Cutaneous vasculitis.
Rheum Dis Clin North Am, 21 (1995), pp. 1097-1113
[20.]
S. Weinstein, W. Piette.
Cutaneous manifestations of antiphospholipid antibody syndrome.
Hematol Oncol Clin North Am, 22 (2008), pp. 67-77
[21.]
P. Criado, E. Rivitti, M. Sotto, J. de Carvalho.
Livedoid vasculopathy as a coagulation disorder.
Autoimmun Rev, 10 (2011), pp. 353-360
[22.]
T. Goerge.
Livedovaskulopathie. Pathogenese, Diagnostik und Therapie des Hautinfarkts.
Hautarzt, 62 (2011), pp. 627-636
[23.]
K. Klein, M. Pittelkow.
Tissue plasminogen activator for treatment of livedoid vasculitis.
Mayo Clin Proc, 67 (1992), pp. 923-933
[24.]
K. Hoogenberg, R. Tupker, L. van Essen, A. Smith, C. Kallenberg.
Successful treatment of ulcerating livedo reticularis with infusions of prostacyclin.
Br J Dermatol, 127 (1992), pp. 64-66
[25.]
M. Yamamoto, K. Danno, H. Shio, S. Imamura.
Antithrombotic treatment in livedo vasculitis.
J Am Acad Dermatol, 18 (1988), pp. 57-62
[26.]
M. Rustin, C. Bunker, P. Dowd.
Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin.
Br J Dermatol, 120 (1989), pp. 101-105
[27.]
G. Hsiao, H. Chiu.
Low-dose danazol in the treatment of livedoid vasculitis.
Dermatol, 194 (1997), pp. 251-255
[28.]
G. Hsiao, H. Chiu.
Livedoid vasculitis. Response to lowdose danazol.
Arch Dermatol, 132 (1996), pp. 749-751
[29.]
B. Hairston, M. Davis, L. Gibson, L. Drage.
Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases.
Arch Dermatol, 139 (2003), pp. 987-990
[30.]
J. Callen.
Livedoid vasculopathy: what it is and how the patient should be evaluated and treated.
Arch Dermatol, 142 (2006), pp. 1481-1482
[31.]
G. Pitarch, M. Rodríguez-Serna, A. Torrijos, V. Oliver, J. Fortea.
Treatment of livedoid vasculopathy with shortcycle intravenous immunoglobulins.
Acta Derm Venereol, 85 (2005), pp. 374-375
[32.]
P. Zeni, E. Finger, M. Scheinberg.
Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy.
Ann Rheum Dis, 67 (2008), pp. 1055-1056
[33.]
S. Miyaki, M. Lockshin, T. Atsumi, D. Branch, R. Brey, R. Cervera, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
J Thromb Haemost, (2006), pp. 295-306
[34.]
R. Rai, C. Sekar, M. Kumaresan.
Antiphospholipid syndrome in dermatology: An update.
Indian J Dermatol Venereol Leprol, 76 (2010), pp. 116-124
[35.]
R. Asherson, C. Francés, L. Iaccarino, M. Khamashta, F. Malacarne, J. Piette, et al.
The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy.
Clin Exp Rheumatol, 24 (2006), pp. 46-51
Copyright © 2011. Asociación Colombiana de Reumatología
Opciones de artículo
Herramientas